Seattle Genetics is a biotechnology company focused on developing monoclonal antibody-based therapeutics for cancer and immunologic diseases. The targeting ability of mAbs provides a means to identify and kill cancer cells while limiting damage to normal tissue. Additionally, the company has more than 130 employees and is located in a high-technology campus in Bothell, Wash. Seattle Genetics was founded in 1997 and is a publicly traded company listed on the NASDAQ under the symbol SGEN.